Genomic regions that influence plasma levels of inflammatory markers in hypertensive sibships

Journal of Human Hypertension

Volumn 22, Issue 2, 2008, Pages 102-110

  Ding, K ^a   Feng, D ^a   de Andrade, M ^a   Mosley Jr , T H ^b   Turner, S T ^a   Boerwinkle, E ^c   Kullo, I J ^a  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; C REACTIVE PROTEIN; FIBRINOGEN;

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; AUTOSOME; BIVARIATE ANALYSIS; CHROMOSOME 10Q; CHROMOSOME 12; CHROMOSOME 2; CHROMOSOME 21; CHROMOSOME ANALYSIS; CONTROLLED STUDY; ETHNIC DIFFERENCE; FEMALE; FIBRINOGEN BLOOD LEVEL; GENE LOCATION; GENETIC ASSOCIATION; GENETIC CORRELATION; GENOME ANALYSIS; GENOTYPE; HERITABILITY; HISPANIC; HUMAN; HYPERTENSION; LINKAGE ANALYSIS; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE MARKER; PLEIOTROPY; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; TURBIDIMETRY; UNIVARIATE ANALYSIS; VARIANCE;

EID: 38349138029     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/sj.jhh.1002297     Document Type: Article

References (60)

1. Wilhelmsen L, Svardsudd K, Korsan-Bengtsen K, Larsson B, Welin L, Tibblin G. Fibrinogen as a risk factor for stroke and myocardial infarction. N Eng J Med 1984; 311: 501-505.
2. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Eng J Med 2000; 342: 836-843.
3. Black S, Kushner I, Samols D. C-reactive protein. J Biol Chem 2004; 279: 48487-48490.
4. Wang Q, Zhu X, Xu Q, Ding X, Chen YE, Song Q. Effect of C-reactive protein on gene expression in vascular endothelial cells. Am J Physiol Heart Circ Physiol 2005; 288: H1539-H1545.
5. Feng D, Lindpaintner K, Larson MG, O'Donnell CJ, Lipinska I, Sutherland PA et al. Platelet glycoprotein IIIa Pl(a) polymorphism, fibrinogen, and platelet aggregability: The Framingham Heart Study. Circulation 2001; 104: 140-144.
6. Ishida T, Tanaka K. Effects of fibrin and fibrinogen-degradation products on the growth of rabbit aortic smooth muscle cells in culture. Atherosclerosis 1982; 44: 161-174.
7. Paul A, Ko KWS, Li L, Yechoor V, McCrory MA, Szalai AJ et al. C-reactive protein accelerates the progression of atherosclerosis in apolipoprotein e-deficient mice. Circulation 2004; 109: 647-655.
8. Robinson DM, Schwahn C, Alte D, John U, Felix SB, Volzke H. Plasma fibrinogen levels are associated with a strong family history of myocardial infarction. Blood Coagul Fibrinolysis 2004; 15: 497-502.
9. Smith EB. Fibrin deposition and fibrin degradation products in atherosclerotic plaques. Thromb Res 1994; 75: 329-335.
10. Ford ES. The metabolic syndrome and C-reactive protein, fibrinogen, and leukocyte count: Findings from the Third National Health and Nutrition Examination Survey. Atherosclerosis 2003; 168: 351-358.
11. Pankow JS, Folsom AR, Cushman M, Borocki IB, Hopkins PN, Eckfeldt JH et al. Familial and genetic determinants of systemic markers of inflammation: The NHLBI family heart study. Atherosclerosis 2001; 154: 681-689.
12. Hamsten A, Iselius L, de Faire U, Blomback M. Genetic and cultural inheritance of plasma fibrinogen concentration. Lancet 1987; 330: 988-991.
13. de Lange M, Snieder H, Ariens RA, Spector TD, Grant PJ. The genetics of haemostasis: A twin study. Lancet 2001; 357: 101-105.
14. Tybjaerg-Hansen A, Agerholm-Larsen B, Humphries SE, Abildgaard S, Schnohr P, Nordestgaard BG. A common mutation (G-455 → A) in the beta-fibrinogen promoter is an independent predictor of plasma fibrinogen, but not of ischemic heart disease. A study of 9127 individuals based on the Copenhagen City Heart Study. J Clin Invest 1997; 99: 3034-3039.
15. Crawford DC, Sanders CL, Qin X, Smith JD, Shephard C,, Wong M et al Genetic variation is associated with C-reactive protein levels in the third National Health and Nutrition Examination Survey. Circulation 2006; 114: 2458-2465.
16. Carlson CS, Aldred SF, Lee PK, Tracy RP, Schwartz SM, Rieder M et al Polymorphisms within the C-reactive protein (CRP) promoter region are associated with plasma CRP levels. Am J Hum Genet 2005; 77 64-77.
17. Kullo IJ, Turner ST, Kardia SL, Mosley Jr TH, Boerwinkle E, de Andrade M. A genome-wide linkage scan for ankle-brachial index in African American and non-Hispanic white subjects participating in the GENOA study. Atherosclerosis 2006; 187: 433-438.
18. Keevil BG, Nicholls SP, Kilpatrick ES. Evaluation of a latex-enhanced immunoturbidimetric assay for measuring low concentrations of C-reactive protein. Ann Clin Biochem 1998; 35(Part 5): 671-673.
19. von Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol 1957; 17: 237-246.
20. Kullo IJ, Seward JB, Bailey KR, Bielak LF, Grossardt BR, Sheedy II PF et al. C-reactive protein is related to arterial wave reflection and stiffness in asymptomatic subjects from the community. Am J Hypertens 2005; 18: 1123-1129.
21. Vogel F, Motulsky A. Human Genetics: Problems and Approaches, 3rd edn. Springer-Verlag: Berlin, 1997.
22. de Andrade M, Atkinson E, Lunde E, Amos C, Chen J. Estimating genetic components of variance in family studies using the Multic routines. In: Technical Report Series No. 78. Department of Health Science Research, Mayo Clinic: Rochester, Minnesota, 2006, http://ndc.mayo.edu/ mayo/research/biostat/upload/78.pdf.
23. Amos CI. Robust variance-components approach for assessing genetic linkage in pedigrees. Am J Hum Genet 1994; 54: 535-543.
24. de Andrade M, Thiel TJ, Yu L, Amos CI. Assessing linkage on chromosome 5 using components of variance approach: Univariate versus multivariate. Genet Epidemiol 1997; 14: 773-778.
25. Turner ST, Kardia SL, Boerwinkle E, de Andrade M. Multivariate linkage analysis of blood pressure and body mass index. Genet Epidemiol 2004; 27: 64-73.
26. Sobel E, Sengul H, Weeks DE. Multipoint estimation of identity-by-descent probabilities at arbitrary positions among marker loci on general pedigrees. Hum Hered 2001; 52: 121-131.
27. Self S, Liang K-Y. Asymptotic properties of maximum likelihood estimators and likelihood ratio tests under non-standard conditions. J Am Stat Assoc 1987; 82: 605-610.
28. Kamphuisen PW, Eikenboom JC, Vos HL, Pablo R, Sturk A, Bertina RM et al. Increased levels of factor VIII and fibrinogen in patients with venous thrombosis are not caused by acute phase reactions. Thromb Haemost 1999; 81: 680-683.
29. Wakayama,H, Hasegawa Y, Kawabe T, Hara T, Matsuo S, Mizuno M et al Abolition of anti-glomerular basement. membrane antibody-mediated glomerulonephritis in FcRgamma-deficient mice. Eur J Immunol 2000; 30: 1182-1190.
30. Falati S, Liu Q, Gross P, Merrill-Skoloff G, Chou J, Vandendries E et al. Accumulation of tissue factor into developing thrombi in vivo is dependent upon micro-particle P-selectin glycoprotein ligand 1 and platelet P-selectip. J Exp Med 2003; 197: 1585-1598.
31. Minnema MC, Chang AC, Jansen PM, Lubbers YT, Pratt BM, Whittaker BG et al. Recombinant human antithrombin III improves survival and attenuates inflammatory responses in baboons lethally challenged with Escherichia coli. Blood 2000; 95: 1117-1123.
32. Ishiguro K, Kojima T, Kadomatsu. K, Nakayama Y, Takagi A, Suzuki M et al. Complete antithrombin deficiency in mice results in embryonic lethality. J Clin Invest 2000; 106: 873-878.
33. Tadokoro S, Tomiyama. Y, Honda S, Kashiwagi H, Kosugi S, Shiraga M et al. Missense mutations in the beta(3) subunit have a different impact on the expression and function between alpha(IIb)beta(3) and alpha(v)beta(3). Blood 2002; 99: 931-938.
34. Chen P, Sun CX, Liu JN. A novel anti-platelet monoclonal antibody (3C7) specific for the complex of integrin alpha IIb beta3 inhibits platelet aggregation and adhesion. J Biol Chem 2005; 280: 25403-25408.
35. Ly DP, Zazzali KM, Corbett SA. De novo expression of the integrin alpha5beta1 regulates alphavbeta3-mediated adhesion and migration on fibrinogen. J Biol Chem 2003; 278: 21878-21885.
36. Oki T, Kitaura. J, Eto K, Lu Y, Maeda-Yamamoto M, Inagaki N et al. Integrin alphaIIbbeta3 induces the adhesion and activation of mast cells through interaction with fibrinogen. J Immunol 2006; 176: 52-60.
37. Flores-Morales A, Stahlberg N, Tollet-Egnell P, Lundeberg J, Malek RL, Quackenbush J et al. Microarray analysis of the in vivo effects of hypophysectomy and growth hormone treatment on gene expression in the rat. Endocrinology 2001; 142: 3163-3176.
38. Braun A, Trigatti BL, Post MJ, Sato K, Simons M, Edelberg JM et al Loss of SR-BI expression leads to the early onset of occlusive atherosclerotic coronary artery disease, spontaneous myocardial infarctions, severe cardiac dysfunction, and premature death in apolipoprotein E-deficient mice. Circ Res 2002; 90: 270-276.
39. Lou JI, Crissey MA, Lou JP, Ciliberto G, Taub R. Interleukin-6-induced STAT3 and AP-1 amplify hepatocyte nuclear factor 1-mediated transactivation of hepatic genes, an adaptive response to liver injury. Mol Cell Biol 2001; 21: 414-424.
40. Pontoglio M, Barra J, Hadchouel M, Doyen A, Kress C, Bach JP et al Hepatocyte nuclear factor 1 inactivation results in hepatic dysfunction, phenylketonuria, and renal Fanconi syndrome. Cell 1996; 84: 575-585.
41. Suresh MV, Singh SK, Agrawal A. Interaction of calcium-bound C-reactive protein with fibronectin is controlled by pH: in vivo implications. J Biol Chem 2004; 279: 52552-52557.
42. Kleemann R, Gervois PP, Verschuren L, Staels B, Princen HM, Kocistra. T. Fibrates down-regulate IL-1-stimulated C-reactive protein gene expression in hepatocytes by reducing nuclear p50-NFkappa B-C/EBP-beta complex formation. Blood 2003; 101: 545-551.
43. Calvano SE, Xiao W, Richards DR, Felciano RM, Baker HV, Cho RJ et al A network-based analysis of systemic inflammation in humans. Nature 2005; 437: 1032-1037.
44. Kullo IJ, Ding K, Boerwinkle E, Turner ST, de Andrade M. Quantitative trait loci influencing low density lipoprotein particle size in African Americans. J Lipid Res 2006; 47. 1457-1462.
45. Kullo IJ, Ding K, Boerwinkle E, Turner ST, Mosley Jr TH, Kardia SL et al. Novel genomic loci influencing plasma homocysteine levels. Stroke 2006; 37: 1703-1709.
46. Best LG, North KE, Tracy RP, Lee ET, Howard BV, Palmieri V et al. Genetic determination of acute phase reactant levels: The strong heart study. Hum Hered 2004; 58: 112-116.
47. Keenan H, Poznik G, Varo N, Schneider J, Almasy L, Warram J et al. Identification of a locus modulating serum C-reactive protein levels on chromosome 5p15. Atherosclerosis 2007; e-pub ahead of print: 6 March 2007.
48. Suk HJ, Ridker PM, Cook NR, Zee RY. Relation of polymorphism. within the C-reactive protein gene and plasma CRP levels. Atherosclerosis 2005; 178: 139-145.
49. Miller DT, Zee RY, Suk Danik J, Kozlowski P, Chasman DI, Lazarus R et al. Association of common CRP gene variants with CRP levels and cardiovascular events. Ann Hum Genet 2005; 69: 623-638.
50. Zee RY, Ridker PM. Polymorphism in the human C-reactive protein (CRP) gene, plasma concentrations of CRP, and the risk of future arterial thrombosis. Atherosclerosis 2002; 162: 217-219.
51. Brull DJ, Serrano N, Zito F, Jones L, Montgomery HE, Rumley A et al Human CRP gene polymorphism. influences CRP levels: Implications for the prediction and pathogenesis of coronary heart disease. Arterioscler Thromb Vasc Biol 2003; 23: 2063-2069.
52. Yang Q, Tofler GH, Cupples LA, Larson MG, Feng D, Lindpaintner K et al. A genome-wide search for genes affecting circulating fibrinogen levels in the Framingham Heart Study. Thromb Res 2003; 110: 57-64.
53. Dupuis J, Larson MG, Vasan RS, Massaro JM, Wilson PW, Lipinska I et al. Genome scan of systemic biomarkers of vascular inflammation in the Framingham Heart Study: Evidence for susceptibility loci on 1q. Atherosclerosis 2005; 182: 307-314.
54. Timpson NJ, Lawlor DA, Harbord RM, Gaunt TR, Day IN, Palmer LJ et al C-reactive protein and its role in metabolic syndrome: Mendelian randomisation study. Lancet 2005; 366: 1954-1959.
55. Kathiresan S, Larson MG, Vasan RS, Guo CY, Gona P, Keaney Jr JF et al Contribution of clinical correlates and 13 C-reactive protein gene polymorphisms to interindividual variability in serum C-reactive protein level. Circulation 2006; 113: 1415-1423.
56. Wang Q, Hunt SC, Xu Q, Chen YE, Province MA, Eckfeldt JH et al. Association study of CRP gene polymorphisms with serum CRP level and cardiovascular risk in the NHLBI family heart study. Am J Physiol Heart Circ Physiol 2006; 291: H2752-H2757.
57. Yeh ET. CRP as a mediator of disease, Circulation 2004; 109: II11-II14.
58. Soria JM, Almasy L, Souto JC, Buil A, Lathrop M, Blangero J et al. A genome search for genetic determinants that influence plasma fibrinogen levels. Arterioscler Thromb Vasc Biol 2005; 25: 1287-1292.
59. Risch N, Merikangas K. The future of genetic studies of complex human diseases. Science 1996; 273: 1516-1517.
60. Kullo IJ, de Andrade M, Boerwinkle E, McConnell JP, Kardia SL, Turner ST. Pleiotropic genetic effects contribute to the correlation between HDL cholesterol, triglycerides, and LDL particle size in hypertensive sibships. Am J Hypertens 2005; 18: 99-103.